Cargando…

Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges

BACKGROUND: Hospital acquired infections (HAI) in the cirrhotic patients contribute to hepatic decompensation. With emergence of bacterial drug resistance, designing the treatment protocol of HA infection has become the foremost challenge. PURPOSE: To analyze the resistance pattern of organisms isol...

Descripción completa

Detalles Bibliográficos
Autores principales: Maindad, Dadasaheb G, Shenoy, Suresh, Shenoy, Suchitra, Gopal, Sandeep, Tantry, Bailuru Vishwanath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934116/
https://www.ncbi.nlm.nih.gov/pubmed/35313728
http://dx.doi.org/10.2147/IDR.S283723
_version_ 1784671793424891904
author Maindad, Dadasaheb G
Shenoy, Suresh
Shenoy, Suchitra
Gopal, Sandeep
Tantry, Bailuru Vishwanath
author_facet Maindad, Dadasaheb G
Shenoy, Suresh
Shenoy, Suchitra
Gopal, Sandeep
Tantry, Bailuru Vishwanath
author_sort Maindad, Dadasaheb G
collection PubMed
description BACKGROUND: Hospital acquired infections (HAI) in the cirrhotic patients contribute to hepatic decompensation. With emergence of bacterial drug resistance, designing the treatment protocol of HA infection has become the foremost challenge. PURPOSE: To analyze the resistance pattern of organisms isolated from hospital-acquired (HA) infections and determine appropriate antibiotics treatment protocols for these infections. STUDY DESIGN: A prospective hospital based observational study was undertaken. PATIENTS AND METHODS: The present study was conducted over 18 months at Kasturba Medical College, Mangalore, Karnataka, India. Patients with suspected HA infections were subjected to clinical, hematological and microbiological evaluation. Antibiotic sensitivity evaluation was undertaken for the bacteria isolated from these patients. RESULTS: During the study period, 398 patients with cirrhosis were 472 times admitted to the hospital for treatment. Out of these patients, 40 patients were diagnosed with 50 HA infections. Fifty five different organisms were isolated from these infections. It was found that these 55 bacteria isolates comprised 30 (54.54%) gram-negative (GN) and 25 (45.45%) gram-positive (GP) bacteria. Quite seriously, extended-spectrum beta-lactamase (ESBL) producers and methicillin-resistant Staphylococcus aureus (MRSA) were detected in 40% and 58% of GN and GP infections respectively. A total of 36 (65.4%) and (14.5%) 8 out of 55 isolated organisms exhibited multi–drug resistance (MDR) and extensive drug resistance (XDR) behavior, respectively. CONCLUSION: Cirrhosis patients with HA infection possess higher prevalence of MDR and XDR infections. In such sick patients, cephalosporin and quinolones are not the appropriate empirical antibiotics. Herein, we propose a tigecycline with carbapenem like meropenem and vancomycin based empirical antibiotics protocol to be prescribed for such patients. De-escalation is advised after the culture sensitivity report is obtained.
format Online
Article
Text
id pubmed-8934116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89341162022-03-20 Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges Maindad, Dadasaheb G Shenoy, Suresh Shenoy, Suchitra Gopal, Sandeep Tantry, Bailuru Vishwanath Infect Drug Resist Original Research BACKGROUND: Hospital acquired infections (HAI) in the cirrhotic patients contribute to hepatic decompensation. With emergence of bacterial drug resistance, designing the treatment protocol of HA infection has become the foremost challenge. PURPOSE: To analyze the resistance pattern of organisms isolated from hospital-acquired (HA) infections and determine appropriate antibiotics treatment protocols for these infections. STUDY DESIGN: A prospective hospital based observational study was undertaken. PATIENTS AND METHODS: The present study was conducted over 18 months at Kasturba Medical College, Mangalore, Karnataka, India. Patients with suspected HA infections were subjected to clinical, hematological and microbiological evaluation. Antibiotic sensitivity evaluation was undertaken for the bacteria isolated from these patients. RESULTS: During the study period, 398 patients with cirrhosis were 472 times admitted to the hospital for treatment. Out of these patients, 40 patients were diagnosed with 50 HA infections. Fifty five different organisms were isolated from these infections. It was found that these 55 bacteria isolates comprised 30 (54.54%) gram-negative (GN) and 25 (45.45%) gram-positive (GP) bacteria. Quite seriously, extended-spectrum beta-lactamase (ESBL) producers and methicillin-resistant Staphylococcus aureus (MRSA) were detected in 40% and 58% of GN and GP infections respectively. A total of 36 (65.4%) and (14.5%) 8 out of 55 isolated organisms exhibited multi–drug resistance (MDR) and extensive drug resistance (XDR) behavior, respectively. CONCLUSION: Cirrhosis patients with HA infection possess higher prevalence of MDR and XDR infections. In such sick patients, cephalosporin and quinolones are not the appropriate empirical antibiotics. Herein, we propose a tigecycline with carbapenem like meropenem and vancomycin based empirical antibiotics protocol to be prescribed for such patients. De-escalation is advised after the culture sensitivity report is obtained. Dove 2022-03-15 /pmc/articles/PMC8934116/ /pubmed/35313728 http://dx.doi.org/10.2147/IDR.S283723 Text en © 2022 Maindad et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Maindad, Dadasaheb G
Shenoy, Suresh
Shenoy, Suchitra
Gopal, Sandeep
Tantry, Bailuru Vishwanath
Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges
title Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges
title_full Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges
title_fullStr Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges
title_full_unstemmed Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges
title_short Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges
title_sort treatment of hospital-acquired infections in patients with cirrhosis – new challenges
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934116/
https://www.ncbi.nlm.nih.gov/pubmed/35313728
http://dx.doi.org/10.2147/IDR.S283723
work_keys_str_mv AT maindaddadasahebg treatmentofhospitalacquiredinfectionsinpatientswithcirrhosisnewchallenges
AT shenoysuresh treatmentofhospitalacquiredinfectionsinpatientswithcirrhosisnewchallenges
AT shenoysuchitra treatmentofhospitalacquiredinfectionsinpatientswithcirrhosisnewchallenges
AT gopalsandeep treatmentofhospitalacquiredinfectionsinpatientswithcirrhosisnewchallenges
AT tantrybailuruvishwanath treatmentofhospitalacquiredinfectionsinpatientswithcirrhosisnewchallenges